Tested radiation alone vs added chemotherapy for EBV-negative after treatment
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This Phase 3 trial compares giving radiation alone versus giving radiation at the same time as chemotherapy for nasopharyngeal cancer. It focuses on people whose EBV test becomes undetectable after one cycle of chemotherapy, to see which approach works best and is safest.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have nasopharyngeal cancer that is non-keratinizing (WHO type II or III), confirmed by a biopsy
- You are 18 to 70 years old
- Your cancer is stage III to IVA
- Your blood EBV DNA was detectable before treatment, but becomes undetectable after one cycle of “neoadjuvant” chemotherapy and stays undetectable during cycles 2 and 3
- You are generally well enough for study treatment (ECOG 0–1) and your blood counts, liver, and kidney tests are within required ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests a stronger treatment approach for people with locally advanced nasopharyngeal cancer whose EBV “DNA” (a cancer-related virus signal in blood) does not go away after one cycle of chemotherapy. It may help improve outcomes by changing treatment based on how the cancer responds early.
This trial tests whether the response to initial chemotherapy can guide the dose of radiation given to patients with Epstein-Barr virus (EBV)-associated nasopharyngeal cancer. The goal is to tailor treatment to reduce side effects while still being effective.
This Phase 3 study tests whether giving a reduced amount of radiotherapy can work as well as the standard dose for certain people with stage II–III nasopharyngeal cancer who respond well after initial chemotherapy. It’s designed for patients whose cancer markers improve after 3 chemotherapy cycles, to potentially reduce treatment side effects while keeping cancer control.
This trial tests combining induction chemotherapy and immunotherapy with radiation, with or without additional chemotherapy, for patients with advanced nasopharyngeal cancer (throat cancer). It aims to see if adding chemotherapy during radiation improves outcomes compared to not having it.
This trial tests whether adding chemotherapy before the usual radiation and chemotherapy treatment can improve outcomes for people with a certain type of nasopharyngeal cancer that has higher risk features. It aims to see if the extra treatment helps control the cancer better.
This Phase 3 trial tests giving chemotherapy first, then either radiation alone or chemotherapy together with radiation. It aims to improve treatment control for people with newly diagnosed, advanced nasopharyngeal cancer.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.